PL383655A1 - Związki heterocykliczne regulujące układ odpornościowy - Google Patents

Związki heterocykliczne regulujące układ odpornościowy

Info

Publication number
PL383655A1
PL383655A1 PL383655A PL38365504A PL383655A1 PL 383655 A1 PL383655 A1 PL 383655A1 PL 383655 A PL383655 A PL 383655A PL 38365504 A PL38365504 A PL 38365504A PL 383655 A1 PL383655 A1 PL 383655A1
Authority
PL
Poland
Prior art keywords
immune system
heterocyclic compounds
adjusting immune
compounds adjusting
solvate
Prior art date
Application number
PL383655A
Other languages
English (en)
Inventor
Ian Richard Mathews
Original Assignee
Medigene Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Medigene Limited filed Critical Medigene Limited
Publication of PL383655A1 publication Critical patent/PL383655A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL383655A 2003-03-14 2004-03-10 Związki heterocykliczne regulujące układ odpornościowy PL383655A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds

Publications (1)

Publication Number Publication Date
PL383655A1 true PL383655A1 (pl) 2008-04-14

Family

ID=32992598

Family Applications (2)

Application Number Title Priority Date Filing Date
PL383655A PL383655A1 (pl) 2003-03-14 2004-03-10 Związki heterocykliczne regulujące układ odpornościowy
PL04719006T PL1603917T3 (pl) 2003-03-14 2004-03-10 Związki heterocykliczne o właściwościach immunomodulujących

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04719006T PL1603917T3 (pl) 2003-03-14 2004-03-10 Związki heterocykliczne o właściwościach immunomodulujących

Country Status (19)

Country Link
US (3) US7276505B2 (pl)
EP (2) EP1603917B1 (pl)
JP (1) JP4892338B2 (pl)
KR (1) KR101133959B1 (pl)
AT (1) ATE489388T1 (pl)
BR (1) BRPI0408365B8 (pl)
CA (1) CA2519063C (pl)
DE (1) DE602004030225D1 (pl)
DK (1) DK1603917T3 (pl)
EA (2) EA009680B1 (pl)
EC (1) ECSP056104A (pl)
IL (1) IL170389A (pl)
MX (1) MXPA05009667A (pl)
NO (1) NO332136B1 (pl)
NZ (1) NZ541973A (pl)
PL (2) PL383655A1 (pl)
PT (1) PT1603917E (pl)
SI (1) SI1603917T1 (pl)
WO (1) WO2004081011A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603917B1 (en) * 2003-03-14 2010-11-24 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
EP1912970A2 (en) * 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008004610A1 (en) * 2006-07-05 2008-01-10 The University Of Tokyo Method of treating genetic disease caused by nonsense mutation
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
GB201021104D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP3193609A4 (en) * 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3558992A4 (en) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔4,3−c〕シンノリン−3−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
ID16283A (id) * 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
US7208495B2 (en) 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1813616B1 (en) 2002-11-22 2013-03-27 Active Biotech AB Pyrazoloquinolines with immunomodulating activity
US7674906B2 (en) 2002-12-16 2010-03-09 Active Biotech Ab Tetracyclic immunomodulatory compounds
EP1603917B1 (en) 2003-03-14 2010-11-24 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
KR101133959B1 (ko) 2012-04-09
EA014080B1 (ru) 2010-08-30
KR20050121681A (ko) 2005-12-27
ATE489388T1 (de) 2010-12-15
AU2004220310A1 (en) 2004-09-23
CA2519063A1 (en) 2004-09-23
JP2006520372A (ja) 2006-09-07
US8309552B2 (en) 2012-11-13
HK1090921A1 (zh) 2007-01-05
EP1603917A1 (en) 2005-12-14
BRPI0408365B1 (pt) 2018-11-21
NO20054710L (no) 2005-12-13
EP1603917B1 (en) 2010-11-24
MXPA05009667A (es) 2006-01-27
PL1603917T3 (pl) 2011-12-30
DE602004030225D1 (de) 2011-01-05
US7598247B2 (en) 2009-10-06
NO332136B1 (no) 2012-07-02
DK1603917T3 (da) 2011-02-28
WO2004081011A1 (en) 2004-09-23
NO20054710D0 (no) 2005-10-13
PT1603917E (pt) 2011-02-04
IL170389A (en) 2013-08-29
CA2519063C (en) 2011-05-10
EA009680B1 (ru) 2008-02-28
US20070021428A1 (en) 2007-01-25
EP2284172A1 (en) 2011-02-16
ECSP056104A (es) 2006-03-01
NZ541973A (en) 2009-06-26
SI1603917T1 (sl) 2011-04-29
BRPI0408365B8 (pt) 2021-05-25
EA200501370A1 (ru) 2006-08-25
US20080045527A1 (en) 2008-02-21
US20090312334A1 (en) 2009-12-17
JP4892338B2 (ja) 2012-03-07
US7276505B2 (en) 2007-10-02
BRPI0408365A (pt) 2006-03-21
EA200702435A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
SI1603917T1 (sl) Imunomodulacijske heterociklične spojine
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
GB0214149D0 (en) Chemical compounds
GB2398781B (en) Kinase inhibitors
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
IL165264A0 (en) Protein kinase inhibitors
TW200732306A (en) Pyrimidine derivatives
MX2012004089A (es) Inhibidores de hsp90.
IL163781A0 (en) Purine derivatives as kinase inhibitors
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
WO2003084938A3 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
AU2003237955A8 (en) Phenyloxyalkanonic acid derivatives as hppar activators
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
EP1477490A4 (en) PYRROLOPYRIMIDINE DERIVATIVE
WO2003059878A3 (en) Thieno (3, 2-b) pyridones as antiviral compounds
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
WO2003059911A3 (en) 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS
GB0325644D0 (en) Immuno ihibitory pyrazolone compounds
GB0215392D0 (en) Chemical compounds
SG149005A1 (en) Process for the preparation of thiazolopyrimidines
MY139348A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
MXPA06004299A (es) Derivados de arilespirofuropiridina.
WO2004078107A3 (fr) Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
MY139098A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts